Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.

Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, Neeser J, Mikail A, Adams J, Sjak-Shie N, Vescio RA, Berenson JR.

Clin Cancer Res. 2003 Mar;9(3):1136-44.

2.

The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.

Berenson JR, Ma HM, Vescio R.

Semin Oncol. 2001 Dec;28(6):626-33. Review.

PMID:
11740821
3.

Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, Cusack JC Jr.

Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):183-93.

PMID:
11316563
4.

Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.

Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, Younes A.

Clin Cancer Res. 2004 May 1;10(9):3207-15. Erratum in: Clin Cancer Res. 2014 Jun 1;20(11):3044.

5.

NF-kappa B as a therapeutic target in multiple myeloma.

Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC.

J Biol Chem. 2002 May 10;277(19):16639-47. Epub 2002 Feb 28.

6.

Molecular sequelae of proteasome inhibition in human multiple myeloma cells.

Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9. Epub 2002 Oct 21.

7.

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, Baldwin AS Jr.

Cancer Res. 2001 May 1;61(9):3535-40.

8.

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC.

Blood. 2009 Jul 30;114(5):1046-52. doi: 10.1182/blood-2009-01-199604. Epub 2009 May 12.

9.

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P, Van Waes C.

Clin Cancer Res. 2001 May;7(5):1419-28.

10.

Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.

Li C, Chen S, Yue P, Deng X, Lonial S, Khuri FR, Sun SY.

J Biol Chem. 2010 May 21;285(21):16096-104. doi: 10.1074/jbc.M109.072694. Epub 2010 Mar 24.

12.

Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.

Jia L, Gopinathan G, Sukumar JT, Gribben JG.

PLoS One. 2012;7(2):e32584. doi: 10.1371/journal.pone.0032584. Epub 2012 Feb 29.

13.
14.

Proteasome inhibition in cancer: development of PS-341.

Adams J.

Semin Oncol. 2001 Dec;28(6):613-9. Review.

PMID:
11740819
15.

The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.

Wang H, Wang X, Li Y, Liao A, Fu B, Pan H, Liu Z, Yang W.

Pharmazie. 2012 Feb;67(2):187-92.

PMID:
22512091
16.

Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis.

Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, Saeed S, Barton K, Alkan S.

Br J Haematol. 2001 Nov;115(2):279-86.

PMID:
11703322
17.

The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.

Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, Beran M.

Haematologica. 2003 Aug;88(8):853-63.

19.

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.

Hideshima H, Yoshida Y, Ikeda H, Hide M, Iwasaki A, Anderson KC, Hideshima T.

Int J Oncol. 2014 Apr;44(4):1171-6. doi: 10.3892/ijo.2014.2273. Epub 2014 Jan 23.

20.

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I.

Mol Cancer Res. 2011 Feb;9(2):183-94. doi: 10.1158/1541-7786.MCR-10-0368. Epub 2011 Jan 11.

Supplemental Content

Support Center